Ann Richmond Archives
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
Jul. 16, 2020—After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post.
Dec. 12, 2019—Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.
Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Nov. 20, 2017—Fifteen Vanderbilt faculty members conducting a range of biomedical and clinical research have been elected fellows of the American Association for the Advancement of Science. Six of the 15 have received funding through the university’s Trans-Institutional Programs initiative, which facilitates research and teaching collaborations across disciplines and are a core pillar of the university’s Academic Strategic Plan.
May. 11, 2017—Vanderbilt University cancer researcher Ann Richmond, Ph.D., 2016 recipient of one of the highest honors for scientific achievement bestowed by the U.S. Department of Veterans Affairs, will be a keynote speaker during a national VA research conference next week at Vanderbilt University School of Medicine.
May. 11, 2017—Ordinary cells can be transformed into cancer cells through epigenetics — changes to DNA that turn genes on or off. Those gene changes can protect cells or make them vulnerable to disease processes including cancer.